Fatal sepsis and systemic inflammatory response syndrome after off-label prasugrel: A case report

American Journal of Therapeutics

Volumn 21, Issue 6, 2014, Pages e229-e233

  Serebruany, Victor L ^a   Kipshidze, Nodar ^a   Pershukov, Igor V ^a   Kuliczkowski, Wiktor ^b   Carnes, Judy ^a   Atar, Dan ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antiplatelet therapy; Case report; Clopidogrel; Off label use; Prasugrel; Sepsis; Systemic inflammatory response syndrome

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PIPERAZINE DERIVATIVE; PRASUGREL; THIOPHENE DERIVATIVE; TICLOPIDINE;

AGED; ANALOGS AND DERIVATIVES; CASE REPORT; CHEMICALLY INDUCED; DOSE RESPONSE; FATALITY; HUMAN; MALE; OFF LABEL DRUG USE; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME;

AGED; ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FATAL OUTCOME; HUMANS; MALE; OFF-LABEL USE; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THIOPHENES; TICLOPIDINE; TIME FACTORS;

EID: 84900299301     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31828fdb1c     Document Type: Article

References (18)

1. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
2. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
3. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015.
4. COMMIT Collaborative Group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet. 2005; 366:1607-1621.
5. Wallentin L, Becker RC, Budaj A, et al; The PLATO investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361:1045-1057.
6. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233-1243.
7. Serebruany VL. Prasugrel and cancer risks: potential causes and implications. Am J Med. 2009;122:407-408.
8. Gross AK, Dunn SP, Feola DJ, et al. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolys. 2013;35:147-154.
9. Blasco-Colmenares E, Perl TM, Guallar E, et al. Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery. Arch Intern Med. 2009; 169:788-796.
10. Welsh RC, Rao SV, Zeymer U, et al; INNOVATE-PCI investigators. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing non-urgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv. 2012;5: 336-346.
11. Cannon CP, Husted S, Harrington RA, et al. Safety, tol-erability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-seg-ment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50: 1844-1851.
12. Fry DE. Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues. Am Surg. 2012;78:1-8.
13. Wolf I, Mouallem M, Rath S, et al. Clopidogrel-induced systemic inflammatory response syndrome. Mayo Clin Proc. 2003;78:618-620.
14. López-Vicente J, Garfia C, López-Medrano F, et al. Hepatic toxicity and clopidogrel-induced systemic inflammatory response syndrome. Rev Esp Cardiol. 2007;60:323-324.
15. Prasugrel Secondary Review. Available at: http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4412b1-00-FDA.htm. Accessed January 9, 2013.
16. Prasugrel prescription insert (2009) Table 4, p.8.
17. Bone RC. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA. 1992;268:3452-3455.
18. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revas-cularization. NEJM. 2012;367:1297-1309.